title: Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant Group.
abstract: To determine the long-term results of high-dose chemotherapy and stem cell support in relapsed or primary refractory Hodgkin disease patients. One hundred and thirty-one patients with relapsed or primary refractory Hodgkin's disease were treated with a dose-intensive therapy protocol consisting of etoposide (2400 mg/m2 continuous intravenous infusion) cyclophosphamide (7200 mg/m2 intravenously), and carmustine (300-600 mg/m2 intravenously) CBVi. All patients had previously failed conventional chemoradiotherapy. Severe toxicities were related to infectious, hepatic, and pulmonary complications. Fatal, regimen-related toxicity was 19%; liver and lung dysfunction, as well as infection, were the most frequent problems. Ninety-one (69%) of the patients achieved a complete response (CR) (95% CI = 59% to 75%) after CBVi and autologous stem cell infusion. With a median follow-up of 5.1 years (range 3.0 to 9.5 years), overall and event-free survival are 44% (95% CI = 33% to 47%) and 38% (95% CI = 28% to 46%) respectively. While univariate analysis did not reveal a statistically significant variable to predict a better response, responsiveness to therapy demonstrated a trend. We conclude that CBVi is an effective therapy for relapsed or refractory Hodgkin's disease, producing long-term, durable remissions.
authors.affiliation: University of Louisville, School of Medicine, James Graham Brown Cancer Center, Division of Hematology/Oncology, KY 40202, USA.
authors.forename: D R
authors.initials: DR
authors.lastname: Fleming
authors.forename: S N
authors.initials: SN
authors.lastname: Wolff
authors.forename: J W
authors.initials: JW
authors.lastname: Fay
authors.forename: R A
authors.initials: RA
authors.lastname: Brown
authors.forename: J P
authors.initials: JP
authors.lastname: Lynch
authors.forename: B J
authors.initials: BJ
authors.lastname: Bolwell
authors.forename: D A
authors.initials: DA
authors.lastname: Stevens
authors.forename: S A
authors.initials: SA
authors.lastname: Goodman
authors.forename: J P
authors.initials: JP
authors.lastname: Greer
authors.forename: R S
authors.initials: RS
authors.lastname: Stein
authors.forename: L A
authors.initials: LA
authors.lastname: Pineiro
authors.forename: R H
authors.initials: RH
authors.lastname: Collins
authors.forename: L J
authors.initials: LJ
authors.lastname: Goldsmith
authors.forename: G P
authors.initials: GP
authors.lastname: Herzig
authors.forename: R H
authors.initials: RH
authors.lastname: Herzig
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002330:Carmustine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005047:Etoposide / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009656:North America; D012008:Recurrence; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D005047:Etoposide; D003520:Cyclophosphamide; D002330:Carmustine